9 terminated. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 3 | 1 | Terminated 1 |
Follow Psychomotor Agitation: new trials by email Literature Review of Psychomotor Agitation trials Research Report on Psychomotor Agitation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nabilone for Agitation in Frontotemporal Dementia Nabilone, Placebo - Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant | Phase 2 | Terminated | Simon Ducharme, MD | 3 | 2023-03-07 | 2026-07-28 |
| INP105 Proof-of-concept Study for the Acute Treatment of Agitation in Adolescents and Young Adults With ASD INP105, Placebo - Agitation in Adolescents and Young Adults With ASD | Phase 2 | Terminated | Impel Pharmaceuticals | 8 | 2022-06-23 | 2023-09-28 |
| An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia BXCL501, Placebo film - Agitation, Dementia | Phase 2 | Terminated | BioXcel Therapeutics Inc | 5 | 2022-02-08 | 2026-08-11 |
| A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression MP-101, Placebo - Psychosis, Dementia | Phase 2 | Terminated | Mediti Pharma Inc. | 81 | 2017-05-04 | 2021-04-01 |
| Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE) Pimavanserin 34 mg, Pimavanserin 20 mg, Placebo - Agitation and Aggression in Alzheimer's Disease | Phase 2 | Terminated | ACADIA Pharmaceuticals Inc. | 111 | 2016-11-01 | 2019-03-28 |
| A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease Group 1 ELND005, Group 2 ELND005 - Alzheimer's Disease | Phase 2 | Terminated | OPKO Health, Inc. | 296 | 2013-01-01 | 2019-10-21 |
| Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants Clonidine HCL, saline - Neonatal Abstinence Syndrome | Phase 2 / Phase 3 | Terminated | Johns Hopkins University | 12 | 2011-07-01 | 2017-09-13 |
| Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145) Preladenant, Placebo, Anticholinergic agents or propanolol - Akathisia, Drug-Induced, Antipsychotic Agents | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 46 | 2007-08-15 | 2018-11-07 |
| Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628) Preladenant, Placebo - Akathisia, Drug-Induced, Dyskinesia, Drug-Induced | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 11 | 2006-07-10 | 2018-11-09 |
Dementia (3) · Aggression (2) · Akathisia, Drug-Induced (2) · Alzheimer Disease (2) · Aphasia, Primary Progressive (1) · Autistic Disorder (1) · Dyskinesia, Drug-Induced (1) · Frontotemporal Dementia (1) · Movement Disorders (1) · Neonatal Abstinence Syndrome (1) · Parkinsonian Disorders (1) · Pick Disease of the Brain (1) · Psychotic Disorders (1)
Dyskinesias (9) · Nervous System Diseases (9) · Neurologic Manifestations (9) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Aberrant Motor Behavior in Dementia (7) · Behavior (7) · Behavioral Symptoms (7) · Neurobehavioral Manifestations (7) · Psychomotor Disorders (7) · Central Nervous System Diseases (6) · Mental Disorders (6) · Brain Diseases (5) · Neurocognitive Disorders (4) · Chemically-Induced Disorders (3)
2-(2-furanyl)-7-(2-(4-(4-(2-methoxyethoxy)phenyl)-1-piperazinyl)ethyl)-7H-pyrazolo(4,3-e)(1,2,4)triazolo(1,5-c)pyrimidine-5-amine (2) · Cholinergic Antagonists (1) · Clonidine (1) · Dexmedetomidine (1) · Haloperidol (1) · LY2812223 (1) · Propranolol (1) · Sodium Chloride (1) · nabilone (1) · pimavanserin (1)
Merck Sharp & Dohme LLC (2) · ACADIA Pharmaceuticals Inc. (1) · BioXcel Therapeutics Inc (1) · Impel Pharmaceuticals (1) · Johns Hopkins University (1) · Mediti Pharma Inc. (1) · OPKO Health, Inc. (1) · Simon Ducharme, MD (1)
United States (6) · Canada (3) · Spain (2) · United Kingdom (2) · Chile (1) · France (1)
BioXcel MM, MD (1) · Craig Erickson, MD (1) · Estelle B Gauda, MD (1) · Matthew Siegel, MD (1) · Stephen Shrewsbury, MD (1)
2005 (1), 2016 (1), R21DA029295 (1)